Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
708 (USA) · Dr. Kim
consented 2013-01-25
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-02 (study day 68.0); relationship: PROBABLE
mild
assessed
Mild APPLICATION SITE SWELLING — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-02 (study day 68.0); relationship: PROBABLE
mild
assessed
Mild SINUS BRADYCARDIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-08 (study day 104.0); relationship: REMOTE
Data queries
No data queries.